Animals
Breast Neoplasms
/ diagnostic imaging
Carbon Radioisotopes
/ pharmacokinetics
Cell Line, Tumor
Drug Evaluation, Preclinical
Female
Hepatobiliary Elimination
Heterografts
Humans
Indazoles
/ chemical synthesis
Inhibitory Concentration 50
MCF-7 Cells
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasm Proteins
/ analysis
Neoplasm Transplantation
Phosphatidylinositol 3-Kinases
/ analysis
Positron-Emission Tomography
Radiopharmaceuticals
/ chemical synthesis
Signal Transduction
Sulfonamides
/ chemical synthesis
Tissue Distribution
Journal
Contrast media & molecular imaging
ISSN: 1555-4317
Titre abrégé: Contrast Media Mol Imaging
Pays: England
ID NLM: 101286760
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
05
2019
revised:
03
08
2019
accepted:
21
08
2019
entrez:
3
12
2019
pubmed:
4
12
2019
medline:
22
7
2020
Statut:
epublish
Résumé
Pictilisib (GDC-0941) is an inhibitor of phosphatidylinositol 3-kinase (PI3K), part of a signaling cascade involved in breast cancer development. The purpose of this study was to evaluate the pharmacokinetics of pictilisib noninvasively by radiolabeling it with
Identifiants
pubmed: 31787861
doi: 10.1155/2019/1760184
pmc: PMC6877939
doi:
Substances chimiques
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
0
Carbon Radioisotopes
0
Carbon-11
0
Indazoles
0
Neoplasm Proteins
0
Radiopharmaceuticals
0
Sulfonamides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1760184Informations de copyright
Copyright © 2019 Na Han et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22
pubmed: 19143635
Invest New Drugs. 2017 Feb;35(1):37-46
pubmed: 27565810
Eur J Pharmacol. 2018 Sep 5;834:188-196
pubmed: 30031797
Nucl Med Biol. 2016 Jan;43(1):101-107
pubmed: 26602328
Circ Res. 2000 Jan 7-21;86(1):15-23
pubmed: 10625300
J Clin Pathol. 2015 Apr;68(4):253-7
pubmed: 25688137
Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1089-99
pubmed: 18239919
Int J Cancer. 2002 Oct 1;101(4):360-70
pubmed: 12209961
Science. 1997 Mar 28;275(5308):1943-7
pubmed: 9072974
JAMA Oncol. 2016 Dec 1;2(12):1565-1573
pubmed: 27388585
Clin Cancer Res. 2015 Jan 1;21(1):77-86
pubmed: 25370471
Nucl Med Biol. 2014 Oct;41(9):749-57
pubmed: 25066021
Curr Top Microbiol Immunol. 2010;347:21-41
pubmed: 20535651
Cancer Cell. 2007 Oct;12(4):395-402
pubmed: 17936563
Clin Cancer Res. 2010 Jul 15;16(14):3670-83
pubmed: 20453058
J Med Chem. 2008 Sep 25;51(18):5522-32
pubmed: 18754654
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Clin Cancer Res. 2011 Feb 15;17(4):667-77
pubmed: 20940279
Int J Cancer. 2016 Feb 15;138(4):1003-12
pubmed: 26334931
Cancer Cell. 2009 May 5;15(5):429-40
pubmed: 19411071
Cancer Res. 2009 Feb 1;69(3):873-8
pubmed: 19155297
Bioorg Med Chem Lett. 2012 Feb 15;22(4):1569-74
pubmed: 22297110
Nat Rev Cancer. 2005 Dec;5(12):921-9
pubmed: 16341083
Mol Imaging Biol. 2010 Apr;12(2):181-91
pubmed: 19784702
J Clin Oncol. 2016 Jun 10;34(17):1987-94
pubmed: 26976426
Br J Cancer. 2011 Mar 29;104(7):1116-25
pubmed: 21407213
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):113-122
pubmed: 26260649
Int J Cancer. 2010 Mar 1;126(5):1121-31
pubmed: 19685490
Mol Pharm. 2017 Nov 6;14(11):3896-3905
pubmed: 29037039
Nucl Med Biol. 2015 Jun;42(6):547-54
pubmed: 25779037